As part of the annual influenza vaccination campaigns, the Flu-M vaccine is now accessible to patients in Russia. It’s a domestic medication containing at least 15 μg of each strain, which meets the WHO (World Health Organization) standards. SPbSRIVS cooperates with WHO actively.
In July 2019, the current antigen for the 2019/2020 influenza strain produced by SPbSRIVS for the WHO system (GISRS) was used by the agency’s main laboratory to produce the standard antigen (the so-called “Standard”), which was assigned the reference number 19/154. The Flu-M vaccine contains antigens of the same quality, which ensures its high quality. Furthermore, the applicable requirements of the European Pharmacopoeia and the State Pharmacopoeia of the Russian Federation limit the concentration of ovalbumin to 1 μg per dose.
Its content in the “Flu-M” vaccine is at most 0.05 μg per dose, which is 20 times lower, thus significantly reducing its reactogenicity, including for those allergic to chicken protein. “The production technology of the Flu-M vaccine ensures obtaining a highly purified antigen,” comments Viktor Trukhin, Director of SPbSRIVS. According to him, “this is a world-class medication produced using a unique preservative-free technology.” The full version of the article is available on the Medical Bulletin portal: https://clck.ru/RM9pa